Search
Search
About
Log in
Join
Experiences with
Castration
Posts
Communities
1,121 public posts
Filter results
Frailty, G-8 Score & PCa outcome.
The overall survival was significantly different between Geriatric 8 scores ≤13 and >13 in metastatic hormone-naïve prostate cancer patients, and between Geriatric 8 scores ≤12 and >12 in
castration
-resistant prostate cancer patients.
The overall survival was significantly different between Geriatric 8 scores ≤13 and >13 in metastatic hormone-naïve prostate cancer patients, and between Geriatric 8 scores ≤12 and >12 in
castration
-resistant prostate cancer patients.
pjoshea13
in
Advanced Prostate Cancer
4 years ago
COVID-19, ADT & the Immune Response
"The atrophy is due to the increased circulating level of sex hormones, and chemical or physical
castration
of an adult results in the thymus increasing in size and activity." *** Who knew that ADT had an upside?
"The atrophy is due to the increased circulating level of sex hormones, and chemical or physical
castration
of an adult results in the thymus increasing in size and activity." *** Who knew that ADT had an upside?
pjoshea13
in
Advanced Prostate Cancer
4 years ago
Any experience cabazitaxel (Jevtana)without prednisone? Referencing preliminary report published Aug 2017.
A preliminary report published in Journal of Cancer, August 2017, entitled ““Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic
Castration
-Resistant Prostate Cancer” studied 91 patients in Italy and showed median survival 9 months with prednisone and 14 months without it, without
A preliminary report published in Journal of Cancer, August 2017, entitled ““Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic
Castration
-Resistant Prostate Cancer” studied 91 patients in Italy and showed median survival 9 months with prednisone and 14 months without it, without
Barbara345
in
Advanced Prostate Cancer
4 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Olaparib for Metastatic Castration-Resistant Prostate Cancer
The New England Journal of Medicine Olaparib for Metastatic
Castration
-Resistant Prostate Cancer N. Engl. J. Med 2020 Apr 28;[EPub Ahead of Print], J de Bono, J Mateo, K Fizazi, e
The New England Journal of Medicine Olaparib for Metastatic
Castration
-Resistant Prostate Cancer N. Engl. J. Med 2020 Apr 28;[EPub Ahead of Print], J de Bono, J Mateo, K Fizazi, e
Balsam01
in
Advanced Prostate Cancer
4 years ago
Rosuvastatin [Crestor] and Abiraterone [Zytiga]
PMID: 32397905 DOI: 10.1177/1078155220923001 Abstract Introduction: Abiraterone acetate is an inhibitor of androgens biosynthesis, approved as first-line treatment in
castration
-resistant prostate cancer and metastatic
castration
-sensitive prostate cancer.
PMID: 32397905 DOI: 10.1177/1078155220923001 Abstract Introduction: Abiraterone acetate is an inhibitor of androgens biosynthesis, approved as first-line treatment in
castration
-resistant prostate cancer and metastatic
castration
-sensitive prostate cancer.
pjoshea13
in
Advanced Prostate Cancer
4 years ago
Reversal of Apalutamide and Darolutamide Aldo-Keto Reductase 1C3-Mediated Resistance by a Small Molecule Inhibitor. 2020 Mar 3
The enzyme acts to circumvent
castration
by producing potent androgens that drive proliferation. Furthermore, AKR1C3 mediates chemotherapeutic resistance to the standard of care; Enzalutamide, a structural analogue of Apalutamide.
The enzyme acts to circumvent
castration
by producing potent androgens that drive proliferation. Furthermore, AKR1C3 mediates chemotherapeutic resistance to the standard of care; Enzalutamide, a structural analogue of Apalutamide.
JLS1
in
Advanced Prostate Cancer
4 years ago
PSA numbers while on QoL Vacation
PSA=0.1 (
castration
ended) 3/20. T=317. PSA=0.2 6/20. T=390. PSA=0.4 My question is the alarm factor of the doubling of my PSA numbers!! I don’t make good decisions anymore but am still “smot” enough to worry myself sick!! Thats a big part of my retardation!!!
PSA=0.1 (
castration
ended) 3/20. T=317. PSA=0.2 6/20. T=390. PSA=0.4 My question is the alarm factor of the doubling of my PSA numbers!! I don’t make good decisions anymore but am still “smot” enough to worry myself sick!! Thats a big part of my retardation!!!
Jimhoy
in
Prostate Cancer Network
4 years ago
HSD3B1 Genotype in Metastatic Castration-Sensitive Prostate Cancer
Interventions Men were randomized to
castration
plus docetaxel, 75 mg/m2, every 3 weeks for 6 cycles or
castration
alone. Main Outcomes and Measures Two-year freedom from CRPC and 5-year overall survival, with results stratified by disease volume.
Interventions Men were randomized to
castration
plus docetaxel, 75 mg/m2, every 3 weeks for 6 cycles or
castration
alone. Main Outcomes and Measures Two-year freedom from CRPC and 5-year overall survival, with results stratified by disease volume.
Balsam01
in
Advanced Prostate Cancer
4 years ago
Surgical Castration. Why is it uncommon?
What surprised me is that many—perhaps most—of the public, including MDs treating prostate cancer patients, assume that surgical
castration
is psychologically more traumatic than chemical
castration
.
What surprised me is that many—perhaps most—of the public, including MDs treating prostate cancer patients, assume that surgical
castration
is psychologically more traumatic than chemical
castration
.
pjoshea13
in
Advanced Prostate Cancer
4 years ago
Testosterone reported < 20
If things go by my experience with six months of Lupron in 2017, my T is expected to remain in
castration
level for the next 3 to 6 months at least. Doctor wanted me to go on ADT vacation to reduce the above mentioned risks to my health.
If things go by my experience with six months of Lupron in 2017, my T is expected to remain in
castration
level for the next 3 to 6 months at least. Doctor wanted me to go on ADT vacation to reduce the above mentioned risks to my health.
dac500
in
Advanced Prostate Cancer
4 years ago
My latest PSA and Testosterone
I don't expect my T to rise above
castration
level in the next 3 to 6 months. Will a small increase in PSA, say by 0.2 or 0.3, indicate possibility of developing castrate resistance? In October 2018, about 10 pelvic and abdominal lymph nodes lighted up with abnormal intense DCFPyL uptake.
I don't expect my T to rise above
castration
level in the next 3 to 6 months. Will a small increase in PSA, say by 0.2 or 0.3, indicate possibility of developing castrate resistance? In October 2018, about 10 pelvic and abdominal lymph nodes lighted up with abnormal intense DCFPyL uptake.
dac500
in
Advanced Prostate Cancer
4 years ago
"Novel Approach to Therapeutic Targeting of" CRPC
-Patrick [1] https://pubmed.ncbi.nlm.nih.gov/32097843-novel-approach-to-therapeutic-targeting-of-
castration
-resistant-prostate-cancer/?
-Patrick [1] https://pubmed.ncbi.nlm.nih.gov/32097843-novel-approach-to-therapeutic-targeting-of-
castration
-resistant-prostate-cancer/?
pjoshea13
in
Advanced Prostate Cancer
4 years ago
Fortis .. FDA Clearance of Two IND Applications for Novel Anti-CD46 Therapeutic for Treatment of Late-Stage Prostate Cancer & Multiple M...
A Phase 1 Study of FOR46 in Patients With Metastatic
Castration
-Resistant Prostate Cancer (mCRPC) https://clinicaltrials.gov/ct2/show/record/NCT03575819?view=record https://www.businesswire.com/news/home/20181106005094/en/Fortis-Therapeutics-Receives-FDA-Clearance-IND-Applications
A Phase 1 Study of FOR46 in Patients With Metastatic
Castration
-Resistant Prostate Cancer (mCRPC) https://clinicaltrials.gov/ct2/show/record/NCT03575819?view=record https://www.businesswire.com/news/home/20181106005094/en/Fortis-Therapeutics-Receives-FDA-Clearance-IND-Applications
JLS1
in
Advanced Prostate Cancer
4 years ago
Dr. Schellhammer's own PC experience and thoughts
Regarding disease progression after failed ADT, "The term '
castration
resistant', I believe, will need further refinement.
Regarding disease progression after failed ADT, "The term '
castration
resistant', I believe, will need further refinement.
noahware
in
Advanced Prostate Cancer
4 years ago
Retrospective Study of Treatment Sequencing
Survival Outcomes for Sequential Use of New Agents in Metastatic
Castration
-Resistant Prostate Cancer Clinical Genitourinary Cancer TAKE-HOME MESSAGE Although there are many new treatments for metastatic
castration
-resistant prostate cancer (MCRPC), including cabazitaxel, enzalutamide, and abiraterone
Survival Outcomes for Sequential Use of New Agents in Metastatic
Castration
-Resistant Prostate Cancer Clinical Genitourinary Cancer TAKE-HOME MESSAGE Although there are many new treatments for metastatic
castration
-resistant prostate cancer (MCRPC), including cabazitaxel, enzalutamide, and abiraterone
cam123
in
Advanced Prostate Cancer
4 years ago
Veru Reports Positive Clinical Results from VERU-111 Phase 1b/2 Trial in Men with Metastatic Castration-Resistant Prostate Cancer, Advancing
I hope someone else can be helped by my sharing this news: https://verupharma.com/news/veru-reports-positive-clinical-results-from-veru-111-phase-1b-2-trial-in-men-with-metastatic-
castration
-resistant-prostate-cancer-advancing-to-pivotal-phase-3-clinical-program/
I hope someone else can be helped by my sharing this news: https://verupharma.com/news/veru-reports-positive-clinical-results-from-veru-111-phase-1b-2-trial-in-men-with-metastatic-
castration
-resistant-prostate-cancer-advancing-to-pivotal-phase-3-clinical-program/
JLS1
in
Advanced Prostate Cancer
4 years ago
First PSA Three Months After Starting ADT Vacation
Previously, when I was on Lupron for six months, it took about six months for Testosterone to come above
castration
level. Making allowance for statistical fluctuation, my PSA stayed at the lowest level over the last six months. It appears that my metastasis is still hormone sensitive.
Previously, when I was on Lupron for six months, it took about six months for Testosterone to come above
castration
level. Making allowance for statistical fluctuation, my PSA stayed at the lowest level over the last six months. It appears that my metastasis is still hormone sensitive.
dac500
in
Advanced Prostate Cancer
4 years ago
ASCO GU 2020: Additional Mechanism of Action of PARP Inhibitor Talazoparib Attacks Prostate Cancer Cells, Spares Normal Cells
This novel treatment works against prostate cancer cells, while selectively sparing normal cells in metastatic,
castration
-resistant prostate cancer. In addition, the treatment is not linked to the side effects of chemotherapy or
castration
treatment.
This novel treatment works against prostate cancer cells, while selectively sparing normal cells in metastatic,
castration
-resistant prostate cancer. In addition, the treatment is not linked to the side effects of chemotherapy or
castration
treatment.
Balsam01
in
Advanced Prostate Cancer
4 years ago
Lynparza [Olaparib] news
Treatment of metastatic
castration
-resistant prostate cancer. www.cancer.net/research-and-advocacy/asco-care-and-treatment-recommendations-patients/treatment-metastatic-
castration
-resistant-prostate-cancer [Last Accessed: November 2019]. 3. Kirby, M., 2011.
Treatment of metastatic
castration
-resistant prostate cancer. www.cancer.net/research-and-advocacy/asco-care-and-treatment-recommendations-patients/treatment-metastatic-
castration
-resistant-prostate-cancer [Last Accessed: November 2019]. 3. Kirby, M., 2011.
pjoshea13
in
Advanced Prostate Cancer
4 years ago
Is There Still a Role for Bilateral Orchidectomy in ADT for Metastatic Prostate Cancer?
Recent Egyption study [1] comparing physical
castration
to Degarelix [Firmagon]. (Degarelix is a GnRH [LHRH] [u]antagonist[/u]. Traditional chemical
castration
drugs such as Lupron are GnRH receptor agonists.)
Recent Egyption study [1] comparing physical
castration
to Degarelix [Firmagon]. (Degarelix is a GnRH [LHRH] [u]antagonist[/u]. Traditional chemical
castration
drugs such as Lupron are GnRH receptor agonists.)
pjoshea13
in
Advanced Prostate Cancer
4 years ago
1
...
30
31
32
...
57
Next page
10
20
30
40
50
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
998 results
Fight Prostate Cancer
67 results
Prostate Cancer Network
25 results
View top 10 communities
Sort by
Most Relevant
Newest